May 28, 2008 --- Cimex AG received the first approval from the BfArM (Federal Institute for Drugs and Medical Devices, Germany) for the antiplatelet agent clopidogrel. Two marketing partners are expected to launch clopidogrel (original product: Plavix® / Iscover® by Bristol-Myers Squibb / Sanofi-Aventis) in Germany.
The approval of clopidogrel in Germany represents a milestone for the Schweizerhall Group. Clopidogrel, developed by Cimex, will be the first more cost-effective alternative of this drug in the German market“, said Luzi A. von Bidder, Chairman of the Board of Schweizerhall Holding AG. Applications for approval in additional European countries are in preparation.
No comments:
Post a Comment